newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - IMMUNOCORE HOLDINGS PLC

  • Explicit Guidance:

    • Enrollment Timelines: Completion of enrollment for the PRISM-MEL (first-line cutaneous melanoma) study is expected in 2027; PFS data readout expected in 2028.
    • Data Readouts: Q2 2027 data release anticipated for the TEBY-MEL (second-line metastatic melanoma) Phase 3 registrational trial.
    • Clinical Program Updates: New HIV data (higher doses up to 1200 mcg) expected to be disclosed at a medical conference in 2026.
    • R&D Milestones: First patient dosed in Type 1 Diabetes (INI program); subsequent Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) data anticipated in the near term, with C-peptide data expected in the MAD phase to assess insulin production preservation.
  • Business-Segment Outlook:

    • ChemTrack (Oncology Core): Growth is transitioning from rapid launch to moderate growth as penetration stabilizes near 70% in the US and 80–90% in some OUS markets.
    • Geographic Growth Drivers: US growth will be driven by deeper penetration into the community setting to increase patient access; OUS growth will rely primarily on new geographic launches and increasing duration of therapy (DOE) in recently launched markets, with DOE currently stabilizing at ~14 months in established markets (up from 10–11 months in clinical trials).
    • Pipeline Expansion (Uveal Melanoma): Combination of ChemTrack plus Bernamafusp (previously named Bernanfusp in transcript) is expected to be a significant long-term growth driver following strong Phase 1 data (ORR 29% vs 11% monotherapy; 2-year OS 70% vs 45%), with progression toward Phase 2/3 anticipated.
    • Metastatic Melanoma: TEBY-MEL Phase 3 study targets HLA-positive second-line metastatic cutaneous melanoma; expected control arm median OS in real-world/registry data is 10–11 months, with historical combination arm data suggesting potential for 16–18 months survival.
    • Autoimmune & Infectious Disease: Strategy to pivot from pure development to partnerships for HIV and Autoimmune programs once value inflection points are reached; Type 1 Diabetes program targets tissue-specific beta-cell preservation via pre-pro-insulin targeting and PD-1 agonism.
  • Market and Competitive Outlook:

    • Competitive Insulation: ChemTrack is viewed as insulated from upcoming oral HLA-negative competitors due to its specific targeting of the HLA-positive patient population and established first-line standard of care status.
    • Market Positioning: Reinforced value proposition based on 5-year data showing doubling of overall survival and the ability to treat patients for extended durations with no cumulative toxicities, a key differentiator against small molecules.
    • Real-World Efficacy: Clinical outcomes (14-month DOE) exceed clinical trial expectations, indicating high physician confidence in the product profile for community-based prescribing.
    • Pipeline Differentiation: The TEBY-MEL control arm is designed to reflect real-world limitations (no current standard of care for this refractory population), with likely treatments comprising PD-1 retreatment (approx. 33%), BRAF retreatment (20–25%), and chemo/palliative care.
  • Macro / Industry Outlook:

    • Reimbursement Impact: Reimbursement landscapes in various countries will dictate the specific options available in the TEBY-MEL control arm (e.g., PD-1 monotherapy vs. Ipilimumab retreatment).
    • Regulatory Environment: No specific changes to regulation or tariffs mentioned; focus remains on achieving statistically significant Overall Survival (OS) benefits to drive practice change in unmet need segments.
    • Market Access: Continued focus on overcoming hesitation in the community setting by leveraging the manageable safety profile (low single-digit adverse events after initial CRS).
  • Strategic Initiatives:

    • Platform Modularity: Leveraging the bispecific platform to expand beyond oncology into autoimmune diseases (Type 1 Diabetes, Atopic Dermatitis) and infectious diseases (HIV functional cure), utilizing tissue-specific targeting.
    • Partnership Strategy: Commitment to act as "efficient stewards" of capital; intent to partner out HIV and Autoimmune programs once clinical value inflection points are proven, while retaining commercialization of core Oncology assets.
    • Capital Efficiency: Utilizing the Type 1 Diabetes program's Phase 1 design to obtain early proof-of-concept via soluble PD-1 biomarkers and C-peptide endpoints, minimizing capital burn prior to partnership discussions.
    • Capacity Expansion: Implicit need for capacity to support new launches in OUS markets and potential future Phase 2/3 studies for combination therapies.
  • Risks and Headwinds to Outlook:

    • Data Readout Delays: TEBY-MEL data timing shifted from end of 2026 to Q2 2027; management cautions against over-interpreting this shift, noting it reflects the flexibility of an OS-driven endpoint and enrollment completion rather than negative signal.
    • Enrollment Dependencies: Future data readouts (PRISM-MEL, INI programs) remain dependent on successful patient enrollment and event accrual rates.
    • Clinical Uncertainty: No therapy has previously demonstrated OS benefit in the TEBY-MEL target population; the Phase 2 data is historical and not from the current combination arm (ChemTrack + Pembrolizumab), creating uncertainty on the magnitude of benefit.
    • Commercial Execution: Growth moderation expected as ChemTrack reaches peak penetration; future growth depends entirely on the success of new launches and the clinical validation of combination therapies.
  • Management Tone on the Future:

    • Confidence: High confidence in the TEBY-MEL study design and the biological rationale for ChemTrack in cutaneous melanoma (high GP100 expression, similar biology to uveal melanoma).
    • Cautious Optimism: Management expresses excitement regarding the "stunning" preliminary data for ChemTrack + Bernamafusp but maintains a disciplined approach to timing and data disclosure (e.g., waiting for higher dose HIV data).
    • Strategic Discipline: Emphasis on capital efficiency and the strategic advantage of partnering non-core assets (HIV/Autoimmune) rather than developing them internally to a late stage.
    • Forward-Looking Sentiment: Positive outlook on the modularity of the platform to drive future inflection points, with a clear roadmap for de-risking programs through early biomarker data (SAD/MAD) in autoimmune indications.
  • Miscellaneous:

    • Financial Position: Company currently holds > $900 million in cash on the balance sheet.
    • Biomarker Focus: Specific focus on soluble PD-1 levels for target engagement and C-peptide as an approvable endpoint for Type 1 Diabetes (referencing Teplizumab precedent).
    • Safety Profile: Differentiation of ChemTrack's safety profile (low cumulative toxicity) compared to small molecule competitors is a key strategic pillar for community adoption.
Company
IMMUNOCORE HOLDINGS PLC
Keywords
IMMUNOCORE HOLDINGS PLC